Serum Biomarker Panel for Synovial Joint Disease Detection in MPS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for specific biomarkers to assess joint disease progression and response to therapy in mucopolysaccharidoses (MPS), as current methods are inadequate for monitoring joint health effectively.
Innovation Solution
The methods involve measuring the levels of specific proteins in a sample from a subject, comparing them to control samples, and administering MPS treatments based on the detected protein levels. The proteins measured can include MMP19, ITIH3, chemerin, CRP, alpha-mannosidase, CD86, alpha-1-microglobulin, prosaposin, secreted phosphoprotein 2, and V-set and immunoglobulin domain containing 4, with fold changes or differences relative to control samples indicating potential joint disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current general methods are used for disease assessment, then broad disease detection is possible, but specific joint disease progression monitoring is inadequate
Solution Approach 1:
The patent segments the disease assessment by identifying specific protein biomarkers (MMP19, ITIH3, chemerin, CRP, and others) that are distinct to joint disease in MPS. Instead of using general disease assessment methods, the invention divides the monitoring task into specific protein level measurements that provide targeted information about joint health status, progression, and treatment response.
2Reliability
If protein level measurements are implemented for early detection, then detection accuracy improves, but measurement and analysis complexity increases
Solution Approach 1:
The patent employs a multi-functional protein panel that serves multiple purposes: diagnosing joint disease, monitoring progression, assessing treatment response, and predicting outcomes. By measuring a set of proteins (MMP19, ITIH3, chemerin, CRP, alpha-mannosidase, CD86, alpha-1-microglobulin, prosaposin, secreted phosphoprotein 2, and V-set and immunoglobulin domain containing 4) that collectively provide comprehensive joint health information, the system achieves reliable early detection while using a unified measurement approach for all these functions.
Data Source
AI summary
Disclosed are methods for detecting synovial joint disease in mucopolysaccharidoses. The methods use a panel of serum biomarker proteins and measure a difference in abundance of one or more of the biomarkers between a subject and a control to identify and treat synovial joint disease in mucopolysaccharidoses. The methods allow for early detection and early therapeutic treatment of synovial joint disease in mucopolysaccharidoses to stop progression of the disease.